Research Topics
| Kim KramerSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Chronic neuroblastomaBrian H Kushner
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer 95:1366-75. 2002..An indolent course is associated with neuroblastoma (NB) in adolescents and adults. In the current study, the authors analyzed this phenomenon in a large series of children with metastatic NB...
Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2Matthias Miederer
Departments of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 10:6985-92. 2004..The (225)Ac-3F8 treatment improved survival 2-fold from 16 to 34 days (P = 0.01). In conclusion, in vivo alpha generators targeted by 3F8 warrant additional study as a possible new approach to the treatment of carcinomatous meningitis...
Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastomaKim Kramer
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 429, New York, NY 10065, USA
J Neurooncol 97:409-18. 2010..The cRIT-salvage regimen for CNS metastases was well tolerated by young patients, despite their prior history of intensive cytotoxic therapies. It has the potential to increase survival with better than expected quality of life...
Establishing successful cerebrospinal fluid flow for radioimmunotherapyKim Kramer
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
J Neurosurg Pediatr 9:316-9. 2012..Endoscopic third ventriculostomy can be considered in patients with programmable shunting devices; normal or slit ventricles do not preclude successful ETV...
Targeted radioimmunotherapy for leptomeningeal cancer using (131)I-3F8K Kramer
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Med Pediatr Oncol 35:716-8. 2000..Intrathecal antibody-based targeted therapies may have clinical potential for patients with leptomeningeal (LM) cancer...
Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8Kim Kramer
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 25:5465-70. 2007..We tested the toxicity, pharmacokinetics, and dosimetry of intraventricular iodine-131-labeled monoclonal antibody 3F8 (131I-3F8) targeting GD2-positive CNS/LM disease in a phase I clinical trial...
Favorable-biology neuroblastoma presenting with leptomeningeal metastases?: a case presentationKim Kramer
Department of Pediatrics, Sloan Kettering Cancer Center, New York, New York, USA
J Pediatr Hematol Oncol 26:703-5. 2004..This case illustrates that some infants with favorable-biology neuroblastoma may be observed without treatment despite the advanced INSS stage...
Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysisKim Kramer
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Pediatr Hematol Oncol 25:601-5. 2003..Although toxicity was generally thought to be mild, the efficacy of such an approach remains unproven...
A focal lesion in the falx cerebri: Harbinger of classic stage 4 neuroblastoma in an infant cured despite residual disease after minimal therapyBrian H Kushner
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Pediatr Blood Cancer 53:1340-2. 2009..The falx cerebri probably does not represent an atypical site for stage 4S NB, but stage 4 NB with favorable biology is sometimes curable with minimal therapy...
High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapyBrian H Kushner
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
Pediatr Blood Cancer 48:430-4. 2007..We assessed the impact on rapid HAMA formation of prior chemotherapy in NB patients...
Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastomaBrian H Kushner
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
J Clin Oncol 22:4888-92. 2004..We now describe similar results with changes that reduce toxicity (fewer cycles, less vincristine, use of granulocyte colony-stimulating factor)...
Hypothyroidism after 131I-monoclonal antibody treatment of neuroblastomaSonal Bhandari
Department of Pediatrics, New York Presbyterian Weill Cornell Medical College, New York, New York, USA
Pediatr Blood Cancer 55:76-80. 2010..To determine the prevalence of and risk factors for primary hypothyroidism following treatment with a radiolabeled monoclonal antibody ((131)I-3F8) in children with neuroblastoma...
Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastomaBrian H Kushner
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
J Clin Oncol 27:1041-6. 2009..Relapse-free survival (RFS) is a powerful measure of treatment efficacy. We describe the sensitivity of standard surveillance studies for detecting relapse of neuroblastoma (NB)...
Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastomaBrian H Kushner
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Pediatr Blood Cancer 53:17-22. 2009..We report a prospective study of secondary leukemia (SL)/myelodysplastic syndrome (MDS) in neuroblastoma (NB) patients treated with > or =5 cycles of dose-intensive chemotherapy...
Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastomaIrene Y Cheung
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 21:1087-93. 2003..Because therapy (myeloablation, immunotherapy, or differentiation) for MRD is applied at the time of clinical remission, objective surrogate markers are needed to gauge treatment efficacy...
Hyperfractionated low-dose (21 Gy) radiotherapy for cranial skeletal metastases in patients with high-risk neuroblastomaBrian H Kushner
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Int J Radiat Oncol Biol Phys 75:1181-6. 2009..To present a large experience (73 patients) using a standard radiotherapy (RT) protocol to prevent relapse in cranial sites where measurable metastatic neuroblastoma (NB), an adverse prognostic marker, is common...
Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastomaBrian H Kushner
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Clin Cancer Res 10:84-7. 2004..067 mg/kg was injected on day 1. With C/I, irinotecan, 50 mg/m(2) was infused i.v. (1 h) on days 1-5 (total, 250 mg/m(2)). Mesna and granulocyte colony-stimulating factor were used...
High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecanBrian H Kushner
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Pediatr Blood Cancer 56:403-8. 2011..We report a retrospective study of a novel regimen for neuroblastoma (NB) resistant to standard induction or salvage chemotherapy which now routinely includes topotecan...
Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastomaBrian H Kushner
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Cancer 116:3054-60. 2010....
Solitary relapse of desmoplastic small round cell tumor detected by positron emission tomography/computed tomographyBrian H Kushner
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
J Clin Oncol 26:4995-6. 2008
Whole neuraxis irradiation to address central nervous system relapse in high-risk neuroblastomaVictoria J Croog
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Int J Radiat Oncol Biol Phys 78:849-54. 2010..This study describes the use of craniospinal irradiation (CSI) for CNS relapse and compares outcomes to patients who received focal radiotherapy (RT)...
Management and outcome of stage 3 neuroblastomaShakeel Modak
Department of Paediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Eur J Cancer 45:90-8. 2009..We describe a single centre approach at Memorial Sloan-Kettering Cancer Centre (MSKCC) from 1991 to 2007 that minimises therapy except for those patients with MYCN-amplified NB...
Transient sialoadenitis: a complication of 131I-metaiodobenzylguanidine therapyShakeel Modak
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Pediatr Blood Cancer 50:1271-3. 2008..5] days. Serum lipase remained normal. Patients did not develop subsequent dry mouth or dysphagia...
Irinotecan plus temozolomide for relapsed or refractory neuroblastomaBrian H Kushner
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 24:5271-6. 2006..To report on an irinotecan and temozolomide regimen for neuroblastoma (NB). Quality of life and minimizing toxicity were major considerations...
Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experienceBrian H Kushner
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Med Pediatr Oncol 41:508-15. 2003..We reviewed the utility of different treatment modalities in a large series of adolescents/adults with neuroblastoma (NB)...
Long-term complications in survivors of advanced stage neuroblastomaCaroline Laverdiere
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Pediatr Blood Cancer 45:324-32. 2005..Few studies have assessed late effects in neuroblastoma (NB) survivors, particularly those with advanced stage disease...
Liver involvement in neuroblastoma: the Memorial Sloan-Kettering Experience supports treatment reduction in young patientsBrian H Kushner
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
Pediatr Blood Cancer 46:278-84. 2006..We reviewed clinical and biologic findings in a series of infants with neuroblastoma (NB) in liver. The aim was to gain insights into improving therapy...
High-dose cyclophosphamide-irinotecan-vincristine for primary refractory neuroblastomaBrian H Kushner
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Eur J Cancer 47:84-9. 2011..We used a novel regimen for neuroblastoma (NB) that had responded inadequately to standard chemotherapy which now includes topotecan in induction or second-line therapy...
Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluidPing He
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065 USA corrected
Eur J Nucl Med Mol Imaging 38:334-42. 2011..We now describe a two-compartment model to account for the ventricular reservoir of (131)I-3F8 and to identify limiting factors that may impact therapeutic ratio...
Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomideBrian H Kushner
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Pediatr Blood Cancer 51:552-4. 2008..Salvage therapy featured 11 cycles of temozolomide. She developed myelodysplastic syndrome with 45,XX,der(7)t(7;21) (p15;q11),-21 at age 24 and refused treatment; 19 months later she was transfusion-dependent but her NB remained in CR...
Ototoxicity from high-dose use of platinum compounds in patients with neuroblastomaBrian H Kushner
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer 107:417-22. 2006....
Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remissionNai Kong V Cheung
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
J Clin Oncol 30:3264-70. 2012..Anti-GD2 monoclonal antibody (MoAb) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) has shown efficacy against neuroblastoma (NB). Prognostic variables that could influence clinical outcome were explored...
Treatment of spinal involvement in neuroblastoma patientsDavid I Sandberg
Department of Surgery, Division of Neurosurgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, N.Y. 10021, USA
Pediatr Neurosurg 39:291-8. 2003..Chemotherapy may be avoided in low-risk patients who are offered potentially curative operations. Patients treated with operations for epidural disease are at high risk of subsequently developing spinal deformity...
Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I studyBrian H Kushner
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
J Clin Oncol 29:1168-74. 2011..We hypothesized that 3F8 dose escalation is possible without increased analgesic requirements in patients pretreated with HM3F8...
Brain-sparing radiotherapy for neuroblastoma skull metastasesSuzanne L Wolden
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Pediatr Blood Cancer 50:1163-8. 2008..The purpose of this study was to describe the technique, outcome and toxicities in patients with high risk NB metastatic to the skull treated with brain-sparing skull radiotherapy (BSRT)...
The impact of gross total resection on local control and survival in high-risk neuroblastomaMichael P La Quaglia
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
J Pediatr Surg 39:412-7; discussion 412-7. 2004..Gross total resection should be part of the management of stage 4 neuroblastoma in patients greater than 1 year of age...
Curability of recurrent disseminated disease after surgery alone for local-regional neuroblastoma using intensive chemotherapy and anti-G(D2) immunotherapyBrian H Kushner
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
J Pediatr Hematol Oncol 25:515-9. 2003..The authors report on a series of patients who had distant recurrences after surgery alone for local-regional neuroblastoma...
Radically different treatment recommendations for newly diagnosed neuroblastoma: pitfalls in assessment of riskBrian H Kushner
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Pediatr Hematol Oncol 26:35-9. 2004..Some patients classified as having high-risk neuroblastoma might actually do well with no cytotoxic therapy...
Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapyBrian H Kushner
Departments of Medical Imaging and Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 21:1082-6. 2003..We present the first report on the effect of MIBG scans on the classification of response to dose-intensive induction therapy...
Five-day courses of irinotecan as palliative therapy for patients with neuroblastomaBrian H Kushner
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer 103:858-62. 2005..Quality of life was a major issue in choosing this regimen for patients whose disease was resistant to standard anti-NB therapies...
Plerixafor plus granulocyte-colony stimulating factor for autologous hematopoietic stem cell mobilization in patients with metastatic neuroblastomaShakeel Modak
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Pediatr Blood Cancer 58:469-71. 2012..Hematopoietic reconstitution was achieved in all three patients receiving plerixafor-primed stem cells after myeloablative therapy. Plerixafor is an effective and safe agent for stem cell collection in patients with NB...
Preliminary results of a phase I trial of prophylactic ethanol-lock administration to prevent mediport catheter-related bloodstream infectionsMark L Kayton
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
J Pediatr Surg 45:1961-6. 2010..Catheter-related bloodstream infections remain costly with no simple prevention. We report preliminary results of a phase I trial of ethanol-lock administration to prevent mediport catheter-related bloodstream infections in children...
Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primatesMatthias Miederer
Department of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Nucl Med 45:129-37. 2004..However, the 3 alpha-emitting daughter elements generated have the potential for significant toxicity as these nuclides are no longer bound to the carrier IgG...
A phase II trial of thalidomide and cyclophosphamide in patients with recurrent or refractory pediatric malignanciesStephen W Gilheeney
Departments of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Pediatr Blood Cancer 49:261-5. 2007..This trial was undertaken to investigate whether the combination of cyclophosphamide and thalidomide would be active against pediatric tumors...
Ifosfamide, carboplatin, and etoposide for neuroblastoma: A high-dose salvage regimen and review of the literatureBrian H Kushner
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York
Cancer 119:665-71. 2013..A major reason for using this regimen was the long time since patients received previous treatment with a platinum compound. The authors also summarized the published experience on ICE in patients with NB...
High-dose carboplatin-irinotecan-temozolomide: Treatment option for neuroblastoma resistant to topotecanBrian H Kushner
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York
Pediatr Blood Cancer 56:403-8. 2011..We report a retrospective study of a novel regimen for neuroblastoma (NB) resistant to standard induction or salvage chemotherapy which now routinely includes topotecan...
Large congenital melanotic nevi in an extremity with neurocutaneous melanocytosisOren J Becher
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, USA
Pediatr Dermatol 26:79-82. 2009..In our case, cerebrospinal fluid studies were not reliable even in the face of florid neurocutaneous melanocytosis involving the leptomeninges and ventricles...
Clinical and diagnostic comparison of neonatal alloimmune thrombocytopenia to non-immune cases of thrombocytopeniaJames B Bussel
Department of Pediatrics, The New York Hospital, Cornell University Medical Center, New York, New York 10021, USA
Pediatr Blood Cancer 45:176-83. 2005..This study was undertaken to compare the outcome of cases of AIT to cases of neonatal thrombocytopenia shown not to be AIT and to identify clinical features that would facilitate the diagnosis...
Variable MR imaging appearances of focal nodular hyperplasia in pediatric cancer patientsRichard K G Do
Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
Pediatr Radiol 41:335-40. 2011..FNH can be incidentally found on CT and MRI and can be misdiagnosed as liver metastasis in patients with an oncological history...
Epidural compression in neuroblastoma: Diagnostic and therapeutic aspectsBruno De Bernardi
Department of Haematology Oncology, Giannina Gaslini Children s Hospital, Largo Gerolamo Gaslini, 5, 16148 Genova, Italy
Cancer Lett 228:283-99. 2005....
Research Grants
- Treating CNS malignancies with 131-I-8H9Kim Kramer; Fiscal Year: 2006..abstract_text> ..
- 131-1 3F8 FOR LEPTOMENINGEAL CANCERSKim Kramer; Fiscal Year: 2007..This study will be the basis for other regional therapies using radiolabeled-antibodies targeting tumor associated antigens for other CNS malignancies. ..
